APA (7th ed.) Citation

Yılmaz, F., Yaşar, S., Tatar, Ö. D., Yıldırım, H. Ç., Güven, D. C., Akyıldız, A., . . . Erman, M. (2024). Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer. BMC Cancer, 24(1), 1. https://doi.org/10.1186/s12885-024-12935-x

Chicago Style (17th ed.) Citation

Yılmaz, Feride, et al. "Bi-weekly Irinotecan Is an Effective and Convenient Regimen in the Treatment of Relapsed or Refractory Small Cell Lung Cancer." BMC Cancer 24, no. 1 (2024): 1. https://doi.org/10.1186/s12885-024-12935-x.

MLA (9th ed.) Citation

Yılmaz, Feride, et al. "Bi-weekly Irinotecan Is an Effective and Convenient Regimen in the Treatment of Relapsed or Refractory Small Cell Lung Cancer." BMC Cancer, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12885-024-12935-x.